Before today's market open, the Cambridge, MA-based biopharmaceutical company reported a net loss of 28 cents per share, wider than the loss of 15 cents per share that analysts were expecting.
Revenue for the period was $15.4 million, missing analysts' estimates of $17.4 million.
"2015 was an extremely productive year during which we completed our corporate transformation into a sustainable and growing commercial enterprise, substantially increased revenues and gross margins, and made significant progress on our clinical and regulatory objectives that we expect will drive current and long-term growth for the company," President and CEO Nick Colangelo said in a statement this morning.
"We believe that we have positioned the company as one of the leading cell therapy and regenerative medicine companies in the industry," he added.
About 1.85 million of the company's shares were traded by this morning vs. its average volume of 1.59 million shares per day.
Separately, TheStreet Ratings Team has a "Sell" rating with a score of D on the stock.
This is driven by a few notable weaknesses, which should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks covered.
Among the areas the team feels are negative, one of the most important has been an overall disappointing return on equity.
Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
You can view the full analysis from the report here: VCEL